CA2586844A1 - Ctla-4 antibody and aromatase inhibitor or combination treatment for breast cancer - Google Patents

Ctla-4 antibody and aromatase inhibitor or combination treatment for breast cancer Download PDF

Info

Publication number
CA2586844A1
CA2586844A1 CA002586844A CA2586844A CA2586844A1 CA 2586844 A1 CA2586844 A1 CA 2586844A1 CA 002586844 A CA002586844 A CA 002586844A CA 2586844 A CA2586844 A CA 2586844A CA 2586844 A1 CA2586844 A1 CA 2586844A1
Authority
CA
Canada
Prior art keywords
antibody
seq
amino acid
acid sequence
ctla4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002586844A
Other languages
English (en)
French (fr)
Inventor
Jesus Gomez-Navarro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc.
Jesus Gomez-Navarro
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc., Jesus Gomez-Navarro filed Critical Pfizer Products Inc.
Publication of CA2586844A1 publication Critical patent/CA2586844A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002586844A 2004-11-04 2005-10-24 Ctla-4 antibody and aromatase inhibitor or combination treatment for breast cancer Abandoned CA2586844A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62485604P 2004-11-04 2004-11-04
US60/624,856 2004-11-04
PCT/IB2005/003307 WO2006048749A1 (en) 2004-11-04 2005-10-24 Ctla-4 antibody and aromatase inhibitor or combination treatment for breast cancer

Publications (1)

Publication Number Publication Date
CA2586844A1 true CA2586844A1 (en) 2006-05-11

Family

ID=35825412

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002586844A Abandoned CA2586844A1 (en) 2004-11-04 2005-10-24 Ctla-4 antibody and aromatase inhibitor or combination treatment for breast cancer

Country Status (15)

Country Link
EP (1) EP1819735A1 (de)
JP (1) JP2008518902A (de)
KR (1) KR20070067702A (de)
CN (1) CN101052655A (de)
AR (1) AR053651A1 (de)
AU (1) AU2005300315A1 (de)
BR (1) BRPI0515735A2 (de)
CA (1) CA2586844A1 (de)
IL (1) IL182244A0 (de)
MX (1) MX2007003804A (de)
NO (1) NO20072576L (de)
RU (1) RU2007114111A (de)
TW (1) TW200621804A (de)
WO (1) WO2006048749A1 (de)
ZA (1) ZA200702577B (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2605796A1 (en) * 2005-04-25 2006-11-02 Pfizer Products Inc. Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor
SG163583A1 (en) * 2005-07-07 2010-08-30 Coley Pharm Group Inc Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
CA2647282A1 (en) * 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
CN101909693A (zh) * 2008-01-08 2010-12-08 百时美施贵宝公司 用于治疗增殖性疾病的抗-ctla4抗体与微管蛋白调节剂的组合
WO2010014784A2 (en) * 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
US8829173B2 (en) 2008-09-26 2014-09-09 Tocagen Inc. Recombinant vectors
EA027693B1 (ru) 2008-09-26 2017-08-31 Токаджен Инк. Рекомбинантный репликационно-компетентный ретровирус с цитозиндезаминазной активностью для генной терапии нарушений клеточной пролиферации
WO2010040105A2 (en) 2008-10-02 2010-04-08 Trubion Pharmaceuticals, Inc. Cd86 antagonist multi-target binding proteins
DK2769737T3 (en) * 2009-07-20 2017-07-24 Bristol Myers Squibb Co COMBINATION OF ANTI-CTLA4 ANTIBODY WITH ETOPOSIDE FOR SYNERGISTIC TREATMENT OF PROLIFERATIVE DISEASES
EP2710137B1 (de) 2011-03-10 2018-09-19 Provectus Pharmatech, Inc. Eine kombination aus bengalrosa und anti-ctla4 antikörper zur behandlung von krebs
KR102004559B1 (ko) 2011-08-30 2019-07-26 아스텍스 파마수티컬스, 인크. 데시타빈 유도체 제제
HUE044352T2 (hu) * 2011-10-14 2019-10-28 Hoffmann La Roche Pertuzumab, Trastuzumab, Docetaxel és Carboplatin korai stádiumú mellrák kezelésére
PE20142406A1 (es) 2012-05-04 2015-01-23 Pfizer Antigenos asociados a prostata y regimenes de inmunoterapia basados en vacuna
CN103768596B (zh) * 2012-10-17 2016-06-22 苏州丁孚靶点生物技术有限公司 用于肿瘤治疗的组合产品、其用途及相关方法
CN104884627A (zh) 2012-10-25 2015-09-02 托卡根公司 具有小型启动子盒的逆转录病毒载体
CN110448566A (zh) 2013-03-01 2019-11-15 阿斯泰克斯制药公司 药物组合
EP3057990B1 (de) * 2013-10-18 2019-09-04 Regeneron Pharmaceuticals, Inc. Zusammensetzungen mit einer kombination aus einem vegf-antagonisten und einem anti-ctla-4-antikörper
JP6768722B2 (ja) 2015-07-02 2020-10-14 大塚製薬株式会社 凍結乾燥医薬組成物
EA201890640A1 (ru) 2015-09-04 2018-09-28 Токаджен Инк. Рекомбинантные векторы, содержащие пептид 2а
CN106883298B (zh) * 2015-12-16 2021-12-17 上海康岱生物医药技术股份有限公司 双特异性偶联抗体及其制法和用途
SG11201805835WA (en) 2016-01-08 2018-08-30 Replimune Ltd Modified oncolytic virus
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
JP7198666B2 (ja) * 2016-08-26 2023-01-04 哲治 奥野 微小血管血流低減剤およびその利用
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
HUE064898T2 (hu) 2017-03-02 2024-04-28 Genentech Inc HER2-pozitív emlõrák adjuváns kezelése
WO2018167780A1 (en) * 2017-03-12 2018-09-20 Yeda Research And Development Co. Ltd. Methods of prognosing and treating cancer
BR112020002280A2 (pt) 2017-08-03 2020-07-28 Otsuka Pharmaceutical Co., Ltd. composto farmacológico e métodos purificação do mesmo
WO2021173870A1 (en) * 2020-02-27 2021-09-02 University Of Washington Composition and method to prepare long-acting injectable suspension containing multiple cancer drugs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL149701A0 (en) * 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies

Also Published As

Publication number Publication date
TW200621804A (en) 2006-07-01
CN101052655A (zh) 2007-10-10
MX2007003804A (es) 2007-04-23
AR053651A1 (es) 2007-05-16
ZA200702577B (en) 2008-07-30
IL182244A0 (en) 2007-09-20
RU2007114111A (ru) 2008-12-10
NO20072576L (no) 2007-08-03
WO2006048749A1 (en) 2006-05-11
KR20070067702A (ko) 2007-06-28
BRPI0515735A2 (pt) 2011-10-11
JP2008518902A (ja) 2008-06-05
AU2005300315A1 (en) 2006-05-11
EP1819735A1 (de) 2007-08-22

Similar Documents

Publication Publication Date Title
CA2586844A1 (en) Ctla-4 antibody and aromatase inhibitor or combination treatment for breast cancer
AU2005264063B2 (en) Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
EP2699598B1 (de) Kombinationen aus anti-4-1bb-antikörpern und adcc-induzierenden antikörpern zur behandlung von krebs
US20090074787A1 (en) Anti-CTLA4 Antibody and Indolinone Combination Therapy for Treatment of Cancer
US20080279865A1 (en) Therapy of Prostate Cancer With Ctla-4 Antibodies and Hormonal Therapy
US20230133118A1 (en) Compositions and methods for treating cancer
WO2021227156A1 (en) Compositions and methods for treating cancer

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued